Concomitant disseminated histoplasmosis and disseminated tuberculosis after tumor necrosis factor inhibitor treatment: a case report

被引:9
作者
Munoz-Oca, Juan E. [1 ]
Morales, Martha L. Villarreal [2 ]
Nieves-Rodriguez, Aracelis [3 ]
Martinez-Bonilla, Lemuel [4 ]
机构
[1] Manati Med Ctr, Family Med Residency Program, POB 1142, Manati, PR 00674 USA
[2] Manati Med Ctr, Dept Med Educ, POB 1142, Manati, PR 00674 USA
[3] Manati Med Ctr, Dept Family Med, POB 1142, Manati, PR 00674 USA
[4] Manati Med Ctr, Dept Internal Med Infect Dis, POB 1142, Manati, PR 00674 USA
关键词
Histoplasmosis; Tuberculosis; Co-infection; TNF-alpha inhibitors; Adalimumab; Case report; PHARMACOKINETICS;
D O I
10.1186/s12879-016-2097-7
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Tumor necrosis factor antagonist inhibitors have transformed the approach to patients with severe autoimmune conditions, such as rheumatoid arthritis. Although the therapy can be highly effective, TNF-alpha inhibitors are associated with an increased risk of opportunistic infections. Case presentation: Here, we report a case of concomitant disseminated histoplasmosis and tuberculosis in a 65-year-old female with rheumatoid arthritis treated with TNF-alpha inhibitor. Both conditions can be found in disseminated form in immunosuppressed hosts, but co-infection is rare with only a few cases having been reported, to our knowledge, all in HIV patients. Conclusions: This case posed a considerable challenge for diagnosis and treatment due to the unusual disseminated co-infection, the overlapping symptoms, and the interactions between medications.
引用
收藏
页数:4
相关论文
共 12 条
[1]   Tuberculosis and Histoplasmosis Co-Infection in AIDS Patients [J].
Agudelo, Carlos A. ;
Restrepo, Carlos A. ;
Molina, Diego A. ;
Tobon, Angela M. ;
Kauffman, Carol A. ;
Murillo, Carolina ;
Restrepo, Angela .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2012, 87 (06) :1094-1098
[2]  
[Anonymous], 2015, Global Tuberculosis Report
[3]  
Anstead GM, 2009, CLIN MYCOLOGY, P355
[4]   Inducing properties of rifabutin, and effects on the pharmacokinetics and metabolism of concomitant drugs [J].
Benedetti, MS .
PHARMACOLOGICAL RESEARCH, 1995, 32 (04) :177-187
[5]   Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial [J].
Conde, Marcus B. ;
Efron, Anne ;
Laredo, Carla ;
Muzy De Souza, Gilvan R. ;
Graca, Nadja P. ;
Cezar, Michelle C. ;
Ram, Malathi ;
Chaudhary, Mohammad A. ;
Bishai, William R. ;
Kritski, Afranio L. ;
Chaisson, Richard E. .
LANCET, 2009, 373 (9670) :1183-1189
[6]   Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk -: A multicenter active-surveillance report [J].
Gómez-Reino, JJ ;
Carmona, L ;
Valverde, VR ;
Mola, EM ;
Montero, MD .
ARTHRITIS AND RHEUMATISM, 2003, 48 (08) :2122-2127
[7]   Effect of rifampicin on the pharmacokinetics of itraconazole in normal volunteers and AIDS patients [J].
Jaruratanasirikul, S ;
Sriwiriyajan, S .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 54 (02) :155-158
[8]   Histoplasmosis: a clinical and laboratory update [J].
Kauffman, Carol A. .
CLINICAL MICROBIOLOGY REVIEWS, 2007, 20 (01) :115-+
[9]  
Lanzafame Massimiliano, 2016, J Clin Tuberc Other Mycobact Dis, V3, P6, DOI 10.1016/j.jctube.2016.03.002
[10]   QuantiFERON TB Gold Testing for Tuberculosis Screening in an Inflammatory Bowel Disease Cohort in the United States [J].
Qumseya, Bashar J. ;
Ananthakrishnan, Ashwin N. ;
Skaros, Sue ;
Bonner, Michael ;
Issa, Mazen ;
Zadvornova, Yelena ;
Naik, Amar ;
Perera, Lilani ;
Binion, David G. .
INFLAMMATORY BOWEL DISEASES, 2011, 17 (01) :77-83